Physician profile
Michael Derrick
NPI 1275828717
$2,600.13
in general payments reported to CMS, 2019-2025
20 companies · $968 in 2025
The $968 reported for 2025 was more than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $225 · 2023: $718 · 2024: $689 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,297 · Education: $78.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,296.78 |
| Education | $78.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $682.07 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $536.41 | 2023-2025 | Fasenra, Airsupra, Tezspire |
| Ars Pharmaceuticals Operations, INC. | $245.04 | 2025 | Neffy |
| Glaxosmithkline, LLC. | $234.57 | 2022-2025 | Nucala, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $164.14 | 2022-2025 | |
| Grifols USA, LLC | $141.37 | 2023-2025 | Xembify |
| Regeneron Healthcare Solutions, INC. | $118.81 | 2024-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $111.76 | 2022-2024 | Cuvitru, Hyqvia, Eohilia |
| Octapharma USA, INC. | $48.88 | 2024-2025 | Cutaquig |
| Genentech USA, INC. | $46.21 | 2022-2024 | Xolair |
| Kaleo, INC. | $41.03 | 2023 | Auvi-Q |
| Csl Behring | $40.65 | 2023 | Hizentra |
| Phadia US INC. | $40.49 | 2023 | Immunocap |
| Pfizer INC. | $40.44 | 2022-2024 | |
| Biocryst US Sales Co., LLC | $21.57 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $20.73 | 2023 | Yuflyma |
| Merck Sharp & Dohme LLC | $18.37 | 2025 | Gardasil 9, M-M-R II, Enflonsia |
| Jubilant Hollisterstier LLC | $17.09 | 2023 | |
| Hikma Pharmaceuticals USA | $16.86 | 2024 | Ryaltris |
| Alk-Abello, INC | $13.64 | 2024 | Alternaria Tenuis, Pre-Pen, Timothy, Standardized |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Derrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.